Roche buys Regor’s CDK inhibitors for $850M upfront amid push to develop 20 ‘transformative’ medicines

Ayisha Sharma

News Reporter

Roche is spending $850 million upfront to buy Regor Pharmaceuticals’ suite of next-generation CDK inhibitors as it doubles down on its strategy to prioritize three …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roche buys Regor’s CDK inhibitors for $850M upfront amid push to develop 20 ‘transformative’ medicines

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Prime Medicine whittles down pipeline, signs gene editing deal with Bristol Myers

Lilly-partnered radiopharma startup Aktis Oncology raises $175M

For some multiple myeloma patients, Carvykti cut risk of death by 45%

The Endpoints 11 winners: Big bets on AI, new frontiers in editing, a neuro renaissance and Chinese chemistry

Cassava and its former execs settle SEC charges for ‘misleading’ Alzheimer’s drug data

3 Tiers for AAV Potency Assay Development Success

Roche buys Re­gor’s CDK in­hibitors for $850M up­front amid push to de­vel­op 20 ‘trans­for­ma­tive’ med­i­cines

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Roche buys Regor’s CDK inhibitors for $850M upfront amid push to develop 20 ‘transformative’ medicines